Indeed, patient sample analyses identified RHBDL2 as a prognostic marker in pancreatic cancer (PC), breast cancer, osteosarcoma, pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (Canzoneri et al. 2014; Rahman et al. 2020; Xiao et al. 2022; Chen et al. 2024). Here, RHBDL2 is linked to osteosarcoma.